Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
NEW YORK--(BUSINESS WIRE)-- #EmergentBioSolutions--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Emergent BioSolutions, In
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
08:01pm, Saturday, 10'th Apr 2021
New York, New York--(Newsfile Corp. - April 10, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such inves
Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)
11:51am, Thursday, 08'th Apr 2021
AUSTIN, Texas--(BUSINESS WIRE)--Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)
Cramer on reports that Emergent Bio received warning over vaccine manufacturing
10:51am, Thursday, 08'th Apr 2021
Emergent BioSolutions was the subject of a warning by a top federal health official last June, according to a New York Times report. The official warned of quality control and other issues at the cont
5 Peter Lynch Growth Stocks to Consider for 2nd Quarter
05:51pm, Tuesday, 06'th Apr 2021
According to the Peter Lynch Growth Screen, a Premium All-in-One Screener template, five stocks with high financial strength, good revenue growth and are trading below the Peter Lynch earnings line as
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS
05:15am, Tuesday, 06'th Apr 2021
NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are adv
Johnson & Johnson Given Control of Emergent BioSolutions Factory That Botched Its Coronavirus Vaccine
07:51pm, Monday, 05'th Apr 2021
The move follows errors in the production of a batch of Johnson & Johnson's jab.
Emergent (EBS) Gets Extra $23M for COVID-19 Vaccine Production
11:22am, Monday, 05'th Apr 2021
Emergent (EBS) receives additional $23 million from BARDA to support further expansion of manufacturing capacity for Johnson & Johnson's COVID-19 vaccine.
J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant
08:20am, Monday, 05'th Apr 2021
The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.
Emergent BioSolutions' Plasma-Based Therapy Candidate Flunks COVID-19 Study; HHS Increases Task Order By $23M
07:14am, Monday, 05'th Apr 2021
Emergent BioSolutions Inc (NYSE: EBS) has announced topline data from Phase 3 trial, dubbed as INSIGHT-013 evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-H
Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson's COVID-19 Vaccine
10:09pm, Sunday, 04'th Apr 2021
GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID
Emergent says experimental COVID-19 treatment failed in Phase 3 trial
09:51am, Friday, 02'nd Apr 2021
Emergent BioSolutions Inc. said Friday that its experimental COVID-19 treatment did not demonstrate a clinical benefit in a late-stage clinical trial. The study was testing Emergent's immunoglobulin c
GAITHERSBURG, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Hu
Why Emergent BioSolutions Crashed Today
06:56pm, Thursday, 01'st Apr 2021
The company appears to have fumbled part of a very high-profile job for a big partner.
Emergent Biosolutions CEO on the vaccine factory mix-up
05:05pm, Thursday, 01'st Apr 2021
Emergent Biosolutions CEO Robert Kramer joins CNBC's Meg Tirrell to discuss the mix up between the ingredients of the AstraZeneca vaccine and the J&J vaccine. However, the mistake was caught early on
